Jun 24, 2020 6:45am EDT iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates
Apr 27, 2020 4:15pm EDT iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™
Apr 09, 2020 7:30am EDT iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute
Mar 26, 2020 4:20pm EDT iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar
Mar 12, 2020 4:45pm EDT iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO
Mar 02, 2020 4:30pm EST iBio, Inc. Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split
